Physician profile
David E Moll
NPI 1780846717
$54,656.75
in general payments reported to CMS, 2019-2025
36 companies · $21K in 2025
The $21K reported for 2025 was more than what 84% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $778 · 2021: $741 · 2022: $1,070 · 2023: $1,029 · 2024: $11K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $3,724 · Travel and Lodging: $3,312 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,733.00 |
| Food and Beverage | $3,723.77 |
| Travel and Lodging | $3,311.51 |
| Education | $315.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $28,461.66 | 2019-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $14,878.69 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,447.12 | 2019-2025 | |
| Abbott Laboratories | $1,942.94 | 2019-2025 | Jot Dx, 2nd Gen Centrimag Primary Console |
| Medtronic Vascular, INC. | $583.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $504.90 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Pfizer INC. | $429.43 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $389.62 | 2020-2025 | Onpattro |
| Amgen INC. | $249.99 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $223.60 | 2020-2025 | Wainua, Andexxa, Farxiga |
| Abiomed | $199.80 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $177.06 | 2019-2024 | Xarelto, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $158.40 | 2020-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $135.26 | 2020-2025 | Lifevest |
| United Therapeutics Corporation | $115.09 | 2024-2025 | Tyvaso, Tyvaso |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.00 | 2023-2025 | Jardiance |
| Esperion Therapeutics, INC. | $70.66 | 2020-2024 | Nexletol |
| Biotronik INC. | $65.00 | 2025 | Acticor 7 Vr-T Dx |
| Atricure, INC. | $63.05 | 2023 | |
| Livanova USA, INC. | $62.51 | 2019 | |
| Kestra Medical Technology Services, INC. | $47.47 | 2022-2025 | Assure Wcd |
| Cvrx, INC. | $45.64 | 2023 | Barostim Neo System |
| Inspire Medical Systems, INC. | $44.98 | 2024 | Inspire |
| Scpharmaceuticals INC. | $38.34 | 2023-2024 | |
| Novo Nordisk INC | $30.80 | 2024-2025 | Wegovy |
| Itamar Medical INC | $23.58 | 2023 | Watchpatone |
| Cleerly, INC. | $23.34 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Medtronic, INC. | $22.75 | 2023 | Corevalve Evolut R |
| Boston Scientific Corporation | $21.96 | 2025 | Watchman Flx |
| Chiesi USA, INC. | $18.86 | 2024 | Kengreal, Cleviprex |
| Philips North America LLC | $17.35 | 2024 | (Ck4) Mcot |
| Kiniksa Pharmaceuticals International, Plc | $17.12 | 2024 | Arcalyst |
| Baxter Healthcare | $16.95 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.34 | 2023 | Inpefa |
| Amarin Pharma, INC. | $16.09 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.98 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.